Equity Investment	9 Months Ended
Sep. 30, 2019
Inventory Disclosure [Abstract]
Equity Investment	Note 4: Equity Investment In 2016, the Company purchased approximately 3.6 million shares of common stock of PACT Pharma, Inc. (PACT Pharma), a privately funded, early-stage biopharmaceutical company focused on adoptive cell therapy and 1.0 million shares of Series A preferred stock. The Company determined the fair value of such investment to be insignificant to the Company’s 2016 financial statements given the start-up nature of operations of PACT Pharma, and it was recorded at a nominal amount. The Company also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma’s achievement of certain valuation thresholds pursuant to a Master Services Agreement between the Company and PACT Pharma (the PACT Agreement), which agreement has since expired. The Company determined PACT Pharma to be a variable interest entity, and that the Company has a variable interest in PACT. However, because the Company is not the primary beneficiary of PACT Pharma, it is not consolidating the results of operations of PACT Pharma in its condensed consolidated financial statements. The Company’s investment in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its condensed consolidated statement of operations and comprehensive loss. During the three months ended September 30, 2019, the Company’s share of PACT Pharma’s losses exceeded the carrying amount of the equity investment. The Company has no obligation to provide cash financing to PACT Pharma and accordingly, no additional losses are being recorded beyond the carrying investment amount. For the three and nine months ended September 30, 2019 the Company recorded $0.4 million and $1.2 million, respectively, for its share of PACT Pharma’s operating losses. The unrecognized equity method losses in excess of the Company’s investment was $0.1 million as of September 30, 2019. For the three and nine months ended September 30, 2018, the Company recorded $0.2 million and $0.6 million, respectively, relating to its share of PACT Pharma’s operating losses. For the three and nine months ended September 30, 2019 and for the year ended December 31, 2018, the Company determined the fair value of the warrants to be insignificant to the condensed consolidated financial statements.

Equity Investment

9 Months Ended

Sep. 30, 2019

Note 4: Equity Investment

In 2016, the Company purchased approximately 3.6 million shares of common stock of PACT Pharma, Inc. (PACT Pharma), a privately funded, early-stage biopharmaceutical company focused on adoptive cell therapy and 1.0 million shares of Series A preferred stock. The Company determined the fair value of such investment to be insignificant to the Company’s 2016 financial statements given the start-up nature of operations of PACT Pharma, and it was recorded at a nominal amount. The Company also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma’s achievement of certain valuation thresholds pursuant to a Master Services Agreement between the Company and PACT Pharma (the PACT Agreement), which agreement has since expired. The Company determined PACT Pharma to be a variable interest entity, and that the Company has a variable interest in PACT. However, because the Company is not the primary beneficiary of PACT Pharma, it is not consolidating the results of operations of PACT Pharma in its condensed consolidated financial statements.

The Company’s investment in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its condensed consolidated statement of operations and comprehensive loss.

During the three months ended September 30, 2019, the Company’s share of PACT Pharma’s losses exceeded the carrying amount of the equity investment. The Company has no obligation to provide cash financing to PACT Pharma and accordingly, no additional losses are being recorded beyond the carrying investment amount. For the three and nine months ended September 30, 2019 the Company recorded $0.4 million and $1.2 million, respectively, for its share of PACT Pharma’s operating losses. The unrecognized equity method losses in excess of the Company’s investment was $0.1 million as of September 30, 2019. For the three and nine months ended September 30, 2018, the Company recorded $0.2 million and $0.6 million, respectively, relating to its share of PACT Pharma’s operating losses.

For the three and nine months ended September 30, 2019 and for the year ended December 31, 2018, the Company determined the fair value of the warrants to be insignificant to the condensed consolidated financial statements.